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Background: Dihydroartemisinin-piperaquine is a new ACT that is administered as single daily dose for three days
and has been demonstrated to be tolerated and highly effective for the treatment of uncomplicated Plasmodium
falciparum malaria. Piperaquine was used alone to replace chloroquine as the first-line treatment for uncomplicated
malaria in China in response to increasing chloroquine resistance in the 1970s. However, the rapid emergence of
piperaquine-resistant strains that resulted in the cessation of its use in China in the 1980s, suggests that there is
cross-resistance between piperaquine and chloroquine. Very few data are available on cross-resistance between
piperaquine and chloroquine, and the data that do exist are often contradictory.
Methods: In total, 280 P. falciparum isolates, collected between April 2008 and June 2012 from patients
hospitalized in France with imported malaria from a malaria-endemic country, were assessed ex vivo for piperaquine
and chloroquine susceptibilities by using the standard 42-hour 3H-hypoxanthine uptake inhibition method. The
chloroquine resistance-associated mutation K76T in pfcrt was also investigated for the 280 isolates.
Results: The IC50 for piperaquine ranged from 9.8 nM to 217.3 nM (mean = 81.3 nM. The IC50 for chloroquine
ranged from 5.0 nM to 1,918 nM (mean = 83.6 nM. A significant but low correlation was observed between the Log
IC50 values for piperaquine and chloroquine (r = 0.145, p < 0.001). However, the coefficient of determination of 0.021
indicates that only 2.1% of the variation in the response to piperaquine is explained by the variation in the
response to chloroquine. The mean value for piperaquine was 74.0 nM in the Pfcrt K76 wild-type group (no = 125)
and 87.7 nM in the 76 T mutant group (no = 155). This difference was not significant (p = 0.875, Mann Whitney
U test).
Conclusions: The present work demonstrates that there was no cross-resistance between piperaquine and
chloroquine among 280 P. falciparum isolates and that piperaquine susceptibility is not associated with pfcrt, the
gene involved in chloroquine resistance. These results confirm the efficacy of piperaquine in association with
dihydroartemisinin and support its use in areas in which parasites are resistant to chloroquine.
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Over the past 20 years, many strains of Plasmodium
falciparum have become resistant to chloroquine and
other anti-malarial drugs [1]. In 2002, the World Health
Organization (WHO) recommended that artemisinin-
based combination therapy (ACT) be used to treat all
cases of uncomplicated malaria. Different formulations




more recently, dihydroartemisinin-piperaquine. Most of
these formulations are available as fixed-dose co-
formulations, which are convenient, facilitate improved
adherence and help prevent misuse.
Dihydroartemisinin-piperaquine (Artekin®, Duo-Cotecxin®,
Eurartesim®) is a new ACT that is administered as single
daily dose for three days and has been demonstrated to
be tolerated and highly effective for the treatment of uncom-
plicated malaria in Asia [2,3] and the treatment of
uncomplicated P. falciparum malaria in Africa [4,5].
Dihydroartemisinin-piperaquine seems to have a better
post-treatment prophylactic effect than artemether-
lumefantrine [6-8] or artesunate-amodiaquine [9]. Since
2012, dihydroartemisinin-piperaquine has been avail-
able for the treatment of uncomplicated malaria
in France.
Piperaquine, a bisquinoline, was used alone to replace
chloroquine as the first-line treatment for uncomplicated
malaria in China in response to increasing chloroquine
resistance in the 1970s. However, the rapid emergence
of piperaquine-resistant strains resulted in the cessation
of its use in China in the 1980s [10].
This rapid emergence of piperaquine-resistant strains
suggests that there is cross-resistance between piperaquine
and chloroquine. Very few data are available on cross-
resistance between piperaquine and chloroquine, and the
data that do exist are often contradictory. A positive sig-
nificant correlation was found for 63 isolates from the
China-Myanmar border area (r = 0.79, p < 0.0001) [11], 54
isolates from Papua New Guinea (r = 0.51, p < 0.001) [12]
and 103 isolates from Cameroon (r = 0.257, p < 0.05) [13],
whereas no significant correlation was observed for 199
isolates from Uganda (r = 0.121, p = 0.15) [14], 115
culture-adapted isolates from Kenya (r = 0.16, p = 0.13)
[15], 23 strains from 16 different countries (r = 0.199, p =
0.366) [16] or 181 isolates of imported malaria from 19
countries (r = 0.036, p = 0.634) [17]. In addition, very few
data are available on the association between piperaquine
susceptibility and polymorphisms in the gene involved in
chloroquine resistance, pfcrt (P. falciparum chloroquine
resistance transporter) [18].
The objectives of the present work were to evaluate the
cross-resistance between piperaquine and chloroquine in280 fresh isolates of P. falciparum and to investigate the
association between piperaquine and chloroquine suscep-
tibility and the K76T mutation in pfcrt.
Methods
Patients and sample collection
In total, 280 P. falciparum isolates were collected between
April 2008 and June 2012 from patients hospitalized in
France with imported malaria from a malaria-endemic
country (Angola, Benin, Burkina Faso, Cameroon, Central
African Republic, Chad, Comoros, Congo, Ivory Coast,
Gabon, Gambia, Ghana, Guinea, India, Madagascar, Mali,
Mauritania, Mozambique, Niger, Senegal, Thailand, Togo,
Zambia). Informed consent was not required for this study
because the sampling procedures and testing are part of
the French national recommendations for the care and
surveillance of malaria. Venous blood samples were
collected in Vacutainer® ACD tubes (Becton Dickinson,
Rutherford, NJ, USA) before treatment and were trans-
ported at 4°C from French hospitals located in Aix en
Provence, Bordeaux, Chambery, Frejus, Grenoble, Lyon,
Marseille, Metz, Montpellier, Nice, Nimes, Pau, Toulon,
Toulouse, and Valence to the Institute of Biomedical
Research of the French Army (IRBA) in Marseille within
72 hours of collection. The Case Report Form was pro-
vided at the same time, either as a paper copy or
electronically.
Thin blood smears were stained using a RAL® kit (Réactifs
RAL, Paris, France) and were examined to determine
P. falciparum density and confirm mono-infection.
Parasitized erythrocytes were washed three times with
RPMI 1640 medium (Invitrogen, Paisley, UK) buffered
with 25 mM HEPES and 25 mM NaHCO3. If parasitaemia
exceeded 0.5%, infected erythrocytes were diluted to 0.5%
with uninfected erythrocytes (human blood type A+) and
re-suspended in RPMI 1640 medium supplemented with
10% human serum (Abcys S.A. Paris, France), for a final
haematocrit of 1.5%. The susceptibility of the 280 isolates
was assessed without culture adaptation.
Drugs
Piperaquine was obtained from Shin Poong Pharm Co.
(Seoul, Korea) and was dissolved first in methanol and
then diluted in water to obtain final concentration ranging
from 0.8 to 1,000 nM. Chloroquine was purchased from
Sigma (Saint Louis, MO, USA) and was dissolved first in
methanol and then diluted in water to final concentrations
ranging from 5 nM to 3,200 nM. Batches of plates were
tested and validated using the chloroquine-susceptible
3D7 strain (West Africa) and the chloroquine-resistant
W2 strain (Indochina) (MR4, Virginia, USA) in three to
six independent experiments using the conditions de-
scribed in the paragraph below. The two strains were syn-
chronized twice with sorbitol before use [19], and clonality
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polymorphic genetic markers msp1 and msp2 and using
microsatellite loci [20,21] and additionally verified each
year by an independent laboratory from the Worldwide
Anti-malarial Resistance Network (WWARN).
Ex vivo assay
For ex vivo isotopic microtests, 200 μl/well of the sus-
pension of synchronous parasitized red blood cells (final
parasitaemia, 0.5%; final haematocrit, 1.5%) were dis-
tributed in 96-well plates pre-dosed with anti-malarial
drugs. Parasite growth was assessed by adding 1 μCi of
tritiated hypoxanthine with a specific activity of 14.1 Ci/
mmol (Perkin-Elmer, Courtaboeuf, France) to each well
at time zero. The plates were then incubated for
42 hours in controlled atmospheric conditions that con-
sisted of 10% O2, 5% CO2, and 85% N2 at 37°C with a
humidity of 95%. Immediately after incubation, plates
were frozen and then thawed to lyse erythrocytes. The
content of each well was collected on standard filter mi-
croplates (Unifilter GF/B; Perkin-Elmer) and washed
using a cell harvester (Filter-Mate Cell Harvester;
Perkin-Elmer). Filter microplates were dried, and 25 μl
of scintillation cocktail (Microscint O; Perkin-Elmer)
was placed in each well. Radioactivity incorporated in
nucleotides by the parasites was measured with a scin-
tillation counter (Top Count; Perkin-Elmer).
The drug concentration able to inhibit 50% of parasite
growth (IC50) was assessed by the drug concentration cor-
responding to 50% of the incorporation of tritiated hypo-
xanthine by the parasite in the drug-free control wells.
The IC50 value was determined by non-linear regression
analysis of log-based dose–response curves (Riasmart,
Packard, Meriden, USA).
Nucleic acid extraction
Total genomic DNA of each strain was isolated using
the QIAamp® DNA Mini kit according to the manufac-
turer’s recommendations (Qiagen, Germany).
Pfcrt single-nucleotide polymorphisms (SNPs)
A 546-nucleotide fragment of the Pfcrt gene (containing
codon 76) was amplified by PCR using CRTP1-sense 5′-
CCG TTA ATA ATA AATACA CGC AG-3′ and CRTP1-
antisense 5′-CGG ATG TTA CAA AAC TAT AGT TAC
C-3′ primers [22]. The reaction mixture for PCR amplifica-
tions included 2.5 μl of genomic DNA, 2.5 μl of 10X reac-
tion buffer (Eurogentec), 0.5 μM of each primer, 200 μM of
a deoxynucleoside triphosphate mixture (dGTP, dATP,
dTTP and dCTP) (Euromedex, Souffelweyersheim,
France), 2.5 mM MgCl2 and 1 unit of RedGoldStar®
DNA polymerase (Eurogentec) in a final volume of
25 μl. The thermal cycler (T3 Biometra, Archamps,
France) was programmed as follows: an initial 94°Cincubation for 5 min, 40 cycles of 94°C for 20 sec, 56°C
for 20 sec, 60°C for 40 sec, and a final 5-min extension
step at 60°C. The PCR products were loaded on a 1.5%
agarose gel containing 0.5 μg/mL ethidium bromide.
The PCR products were diluted 1:100 in distilled water, and
2.5 μl of the final dilution was used for the second PCR.
This PCR amplified a 275 bp segment around the mutation
using a common inner primer CRTP3-sense 5′-TGA CGA
GCG TTA TAG AG-3′ coupled with either CRTP4m-
antisense 5′-GTT CTT TTA GCA AAA ATT G-3′ (de-
tects the 76 T codon) or CRTP4w-antisense 5′-GTT CTT
TTA GCA AAA ATT T-3′ (detects the 76 K codon). The
reaction mixture for the PCR amplifications included
2.5 μl of diluted PCR product, 2.5 μl of 10X reaction buffer
(Eurogentec), 0.5 μM of each primer, 200 μM deoxynu-
cleoside triphosphate mixture (dGTP, dATP, dTTP and
dCTP) (Euromedex, Souffelweyersheim, France), 1.5 mM
MgCl2 and 0.75 U of RedGoldStar® DNA polymerase
(Eurogentec) in a final volume of 25 μl.
The PCR conditions were at 94°C for 5 min, 15 cycles at
94°C for 20 sec, 48.5°C for 20 sec, 64°C for 40 sec, and a
final 5-min extension step at 64°C. Purified genomic DNA
from P. falciparum clones 3D7 (chloroquine susceptible)
and W2 (chloroquine resistant) were used as positive con-
trols, and water and human DNA were used as negative
controls. The PCR products from the amplification reac-
tions were evaluated by electrophoresis on 2% agarose gels.
Statistical analysis
Data were analysed using R software (version 2.10.1). As-
sessment of standard anti-malarial drugs cross-resistance
between piperaquine and chloroquine drugs was mea-
sured by pairwise correlation of IC50 values of all isolates
and estimated by coefficient of correlation of Pearson (r)
and coefficient of determination (r2). Differences between
the chloroquine and piperaquine IC50 values of isolates
and Pfcrt K76T were compared using the Mann Whitney
U test.
Results
The IC50 for piperaquine ranged from 9.8 nM to 217.3 nM
(mean = 81.3 nM; 95% confidence interval 71.3-92.7). The
IC50 for chloroquine ranged from 5.0 nM to 1918 nM
(mean = 83.6 nM; 95% confidence interval 71.0-98.3). Fifty
three% of the isolates showed IC50 > 100 nM for chloro-
quine. A significant correlation was observed between the
Log IC50 values for piperaquine and chloroquine (r = 0.145,
p < 0.001) (Figure 1).
Of the 280 isolates, 125 were wild type (K76), and 155
were mutated (76T). The mean value for chloroquine IC50
was 31.3 nM (95% CI 25.4-38.7) in the wild-type group
and 184.5 (95% CI 157.4-215.8) in the mutant group. This
difference was significant (p = 0.001, Mann Whitney U
test). The mean value for piperaquine was 74.0 nM (95%
Figure 1 Pearson’s correlation analysis of the Log IC50 values of piperaquine and chloroquine.
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71.9-106.9) in the mutant group. This difference was not
significant (p = 0.875, Mann Whitney U test).
Discussion
The IC50 for piperaquine ranged from 9.8 nM to 217.3
nM (mean = 81.3 nM; 95% confidence interval 71.3-92.7).
These values are greater than the geometric means for iso-
lates from Cameroon (geometric mean = 39 nM) [13], the
Thai-Burmese border (49 nM) [23], Kenya (50 nM) [15],
Uganda (6.1 nM) [14], Indonesia (21.8 nM) [24], and
Papua New Guinea [12]. The comparison of IC50s across
studies is likely hampered by different methodology in
assessing these. The isolate with the highest IC50 for piper-
aquine (217.3 nM) was also resistant to chloroquine
(1,029 nM). There is no consensus threshold indicating
piperaquine in vitro resistance or reduced susceptibility.
In vitro cross-resistance was assessed using the pairwise
correlation of the Log IC50 values of the 280 isolates
(Figure 1). A significant correlation was observed between
the Log IC50 values for piperaquine and chloroquine (r =
0.145, p <0.001). However, this value is too low to suggest
that there is cross-resistance between piperaquine and
chloroquine. For a correlation to imply that two com-
pounds share common mechanisms of action or resistance,
which could induce cross-resistance, the coefficient of de-
termination (r2) must be high. Here, the coefficient of de-
termination of 0.021 indicates that only 2.1% of the
variation in the response to piperaquine is explained by the
variation in the response to chloroquine. These data are in
accordance with the majority of the previous studies, which
found weak coefficients of determination [13-17]. This re-
sult suggests that piperaquine and chloroquine do not share
common mechanisms of resistance. However, positive sig-
nificant correlation was found for 63 isolates from the
China-Myanmar border area (r = 0.79, p < 0.0001) [11] and
54 isolates from Papua New Guinea (r = 0.51, p < 0.001)[12]. This difference in in vitro cross-resistance might be
explained by the low sample numbers in these two studies
and by geographical strain differences.
As expected, the 76T mutation is associated with chloro-
quine resistance (p = 0.001, Kruskal-Wallis test). The mean
value for piperaquine was 74.0 nM (95% CI 62.9-87.0) in
the wild-type group and 87.7 (95% CI 71.9-106.9) in
the mutant group. This difference was not significant (p =
0.862, Kruskal-Wallis test). These data suggest that the
76T mutation is not associated with piperaquine-decreased
susceptibility. These data are in accordance with previous
data on 23 strains from 15 countries of Africa, Asia and
South America [16] and 115 isolates from Kenya [15]. The
absence of cross-resistance between piperaquine and
chloroquine may be explained by the absence of an associ-
ation between piperaquine resistance and pfcrt. The very
weak correlation between piperaquine and chloroquine re-
sponses (only 2.1% of the variation in the response to
piperaquine is explained by the variation in the response to
chloroquine) could be explained by other polymorphisms
involved in very minor way in chloroquine resistance, such
as pfmdr1 SNPs or copy number. Fieldwork has shown
that the predictive value for chloroquine resistance and
point mutations in the pfmdr1 sequence resulting in amino
acid changes varies depending on the geographic area
[25,26]. Point mutations, most notably N86Y, have
been associated with a decrease in the chloroquine sus-
ceptibility [27]. However, in some of these epidemio-
logical studies, the number of chloroquine-susceptible
samples is too limited to provide statistically meaning-
ful analysis [26,28]. Using precautions, no or only weak
relationships are established in P. falciparum between
chloroquine resistance and mutations in pfmdr1 [25].
However, previous works demonstrated that polymor-
phisms in pfmdr1 gene or copy number are not associ-
ated with decreased susceptibility to piperaquine
[11,15,16].
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that showed that genetically modified parasites with
CVIET haplotypes had reduced susceptibility to pipera-
quine [29].
The present work demonstrated that piperaquine exhibits
currently no cross-resistance with chloroquine in African P.
falciparum isolates and that resistance to piperaquine is not
associated with pfcrt, the gene involved in chloroquine re-
sistance. The validity of this conclusion should be further
supported by analysing more isolates, especially from South
America and Asia. In addition, copy number variation of a
chromosome 5 region, a genetic marker associated with
high piperaquine IC50 in a piperaquine-selected P. falcip-
arum line [30], should be evaluated for reduced ex vivo sus-
ceptibility. Nevertheless, these results confirm the efficacy
of piperaquine in association with dihydroartemisinin and
support its use in areas in which parasites are resistant to
chloroquine.
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